Models using plasma A\u03b242\/A\u03b240 to predict probability of CSF A\u03b242\/A\u03b240 positivity not affected by race<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, April 25, 2022 (HealthDay News) — Some models for predicting brain amyloidosis are affected by race and may not provide consistent results across racial groups, according to a study published online April 21 in Neurology<\/em>.<\/p>\n Suzanne E. Schindler, M.D., Ph.D., from the Washington University School of Medicine in St. Louis, and colleagues examined whether plasma biomarkers of amyloid, tau, and neuroaxonal injury identify brain injury consistently across racial groups. Individuals who self-identified as African American were matched to self-identified non-Hispanic Whites by age, APOE<\/em> \u00ce\u00b54 carrier status, and cognitive status; 76 pairs were included.<\/p>\n The researchers found that compared with non-Hispanic Whites, African Americans were less likely to have brain amyloidosis by cerebrospinal fluid (CSF) A\u00ce\u00b242\/A\u00ce\u00b240 (22 versus 43 percent positive). Models predicting CSF A\u00ce\u00b242\/A\u00ce\u00b240 status based on plasma biomarker levels had areas under the receiver operating characteristic curve of 0.86 for A\u00ce\u00b242\/A\u00ce\u00b240, 0.76 for p-tau181, 0.69 for p-tau231, and 0.64 for neurofilament light chain (NfL). In models predicting CSF A\u00ce\u00b242\/A\u00ce\u00b240 status with plasma A\u00ce\u00b242\/A\u00ce\u00b240, which included age, sex, APOE<\/em> \u00ce\u00b54 carrier status, race, and cognitive status as covariates, the probability of CSF A\u00ce\u00b242\/A\u00ce\u00b240 positivity was not affected by race. African Americans had a lower probability of CSF A\u00ce\u00b242\/A\u00ce\u00b240 positivity in similar models based on plasma p-tau181, p-tau231, and NfL (odds ratios, 0.31, 0.30, and 0.27, respectively). Similar findings were seen in models of amyloid positron emission tomography status.<\/strong><\/p>\n “Rather than trying to adjust for race in some way, it would be better to use tests that perform equally well in all individuals,” Schindler said in a statement.<\/p>\n Several authors are employees of C\u00e2\u0082\u0082N Diagnostics.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n